The National Institutes of Health (NIH) is a leading biomedical research facility in the United States, operating under the Department of Health and Human Services. Established in 1887 and based in Bethesda, Maryland, NIH is the primary agency responsible for biomedical and health-related research in the country. It comprises 27 separate institutes and centers, each focusing on different disciplines within biomedical science. NIH conducts its own scientific research through the Intramural Research Program and provides significant funding for research at external institutions via the Extramural Research Program. With a workforce that includes 1,200 principal investigators and over 4,000 postdoctoral fellows, NIH has been instrumental in major medical breakthroughs, such as the development of vaccines for hepatitis and human papillomavirus, as well as the discovery of treatments for various health conditions. As the world's largest source of medical research funding, NIH continues to advance scientific knowledge and contribute to public health improvements.
RA Capital Management is a Boston-based investment advisor founded in 2004, specializing in the life sciences and healthcare sectors. The firm focuses on early-stage companies developing innovative technologies, products, and services in drug development, medical devices, diagnostics, and research tools. With a team of professionals trained in biology, chemistry, and medicine, RA Capital Management leverages its extensive industry and business development experience to identify and invest in promising healthcare ventures. As a Registered Investment Adviser, the firm employs a strategic approach that includes both venture capital investments and a hedge fund strategy, targeting opportunities primarily in the United States and Europe.
SOSV is a global venture capital firm based in Princeton, New Jersey, founded in 1995. It specializes in early-stage investments, focusing on deep technology innovations that address human and planetary health. The firm operates startup development programs, notably HAX and IndieBio, which provide resources, facilities, and lab equipment to accelerate the growth of promising startups. SOSV supports companies from their inception through various funding stages, including seed and series A rounds, while offering ongoing assistance to help them scale and attract additional investors. By concentrating on revolutionary technologies and cross-border markets, particularly in Asia, SOSV aims to foster significant advancements that benefit humanity and the environment.
The National Science Foundation (NSF) is an independent federal agency established in 1950 and based in Alexandria, Virginia. It is dedicated to supporting research and education in science and engineering across a wide range of disciplines. The NSF provides significant non-dilutive funding, up to $1.5 million, to startups and small businesses through its America's Seed Fund initiative, which is part of the Small Business Innovation Research (SBIR) program mandated by Congress. With an operating budget of approximately $7.8 billion, the NSF is committed to advancing fundamental research and education, thus fostering innovation and technological development in the United States.
OrbiMed is a healthcare-focused investment firm based in New York City, established in 1989. The firm specializes in providing a range of financing solutions, including bridge loans, senior debt, and structured debt capital for both commercial-stage public and private healthcare companies. OrbiMed invests across various sectors within the healthcare industry, such as pharmaceuticals, life sciences, digital health, medical devices, biopharmaceuticals, diagnostics, healthcare technology, and biotechnology. With approximately $5 billion in assets under management, OrbiMed aims to support a spectrum of healthcare companies, from early-stage ventures to established multinational corporations.
Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, founded in 2006. With additional offices in Beijing, Suzhou, Hong Kong, and Singapore, the firm focuses on early to growth-stage investments across various sectors, including healthcare, information technology, consumer goods, mobile internet, artificial intelligence, and clean technology. Qiming Venture Partners has a strong track record, having invested in over 530 innovative companies, with more than 200 achieving successful exits through public offerings or mergers and acquisitions. The firm is recognized for its deep technical expertise and hands-on operational support, making it a preferred partner for CEOs and startups seeking to scale their operations. Its partners are often sought after as board members, reflecting their status as respected business leaders and thought leaders in the venture capital landscape.
The European Innovation Council (EIC), established in 2020 and headquartered in Brussels, Belgium, is dedicated to supporting high-potential innovators, entrepreneurs, small enterprises, and researchers. Its primary focus is on fostering early-stage startups that demonstrate significant environmental, social, and governance (ESG) impacts. The EIC collaborates with private investors to co-invest in ventures, particularly within the deep technology sector, aiming to drive innovation and sustainable development across Europe. By providing financial backing and resources, the EIC seeks to enhance the growth potential of promising startups and contribute to a more innovative and competitive European economy.
Innovate U.K. is a NPO that offers funding services to support science and technology innovations. The organization offers services and information on births, deaths, marriages, business, self-employed, childcare, parenting, citizenship, law, disabled persons, transportation, education, environment, housing, money, tax, travel, immigration, and jobs. Innovate U.K. is based in Swindon.
Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.
Perceptive Advisors LLC is an investment management firm established in 1999, with headquarters in New York City and an additional office in Boston. The firm specializes in supporting the life sciences sector, investing primarily in biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. Perceptive Advisors engages in venture capital and incubation, making equity investments ranging from $10 million to $200 million in both private and public companies. It manages client-focused equity portfolios and employs a long/short equity strategy as part of its hedging techniques. Additionally, the firm conducts in-house research and utilizes technical analysis to inform its investment decisions. Perceptive Advisors also provides customized debt financing solutions through its Perceptive Credit Opportunities Fund, catering to the evolving needs of healthcare companies.
Novo Holdings is a Danish holding and investment firm based in Copenhagen, wholly owned by the Novo Nordisk Foundation. Established in 1999, it manages the Foundation's financial assets and aims to ensure sufficient dividends to support its grant obligations for medical and scientific research. Novo Holdings primarily invests in the life science sector, maintaining a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments. It holds a significant ownership stake in Novo Nordisk A/S and Novozymes A/S, ensuring a material influence over these companies. The firm actively participates in their governance and is committed to supporting early-stage applied research in life sciences through initiatives like Novo Seeds. By investing in both early and later-stage life science companies, Novo Holdings seeks to balance financial risk while aiming for high returns, all within a framework of shared values and management principles across the Novo Group.
GV Investment Managers is a private equity firm founded in 2000 and based in Stamford, Connecticut. The firm specializes in impact investing, private equity, and portfolio management services. It focuses on sectors such as life sciences, consumer products, enterprise solutions, cryptocurrency, climate technology, and frontier innovations. With Alphabet as its sole limited partner, GV Investment Managers primarily targets investments in North America and Europe. The firm collaborates with operating partners who assist startups in areas such as design, diversity and inclusion, talent acquisition, and engineering, while also facilitating connections with Google for technological support and expertise.
MedTech Innovator is the industry’s nonprofit global competition and accelerator for medical device, digital health and diagnostic companies. Our mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator annually features 100 companies that address one or more of the transformative themes identified in an annual survey of leading manufacturers and providers.
MassChallenge is a global nonprofit startup accelerator headquartered in Boston, Massachusetts, founded in 2009. It supports early-stage entrepreneurs from various industries, including technology, healthcare, and finance, by providing mentorship, resources, and networking opportunities. With locations in countries such as Israel, Mexico, Switzerland, and Texas, MassChallenge operates a non-equity model, allowing startups to retain full ownership while benefiting from expert guidance and connections. The accelerator conducts various programs tailored to specific sectors, such as MassChallenge HealthTech and MassChallenge FinTech, which facilitate partnerships between startups and established enterprises to drive innovation and market growth. Through its extensive global network, MassChallenge aims to strengthen the innovation ecosystem and empower high-potential startups to create meaningful impact.
ARCH Venture Partners, founded in 1986 and based in Chicago, Illinois, is a venture capital firm that specializes in investing in early-stage technology companies, particularly in the life sciences sector. The firm focuses on innovations that emerge from academic research institutions and national laboratories, making it a recognized leader in the commercialization of such technologies. ARCH invests conservatively in seed rounds to mitigate risk and subsequently leads or co-leads further financing rounds, aiming for a seat on the Board of Directors. Its investment strategy encompasses a wide range of sectors, including biotechnology, pharmaceuticals, advanced materials, and clean technology, among others. ARCH primarily invests in the United States while also targeting opportunities in countries like Canada, Ireland, South Korea, China, and Japan. The firm has raised over $3 billion across ten venture funds and has supported more than 150 companies in their early capital rounds.
Alumni Ventures Group, LLC is a venture capital firm based in Manchester, New Hampshire, founded in 2013. The firm specializes in seed and early-stage investments, as well as late-stage pre-IPO opportunities, with a flexible approach that is sector and geographic agnostic. Alumni Ventures aims to provide high-quality, diversified venture portfolios to individual investors, particularly accredited alumni from top entrepreneurial schools, who may not have had access to venture capital previously. The firm focuses on backing companies that have an alumni connection and are led by established institutional investors with expertise in their respective fields. Additionally, Alumni Ventures offers focused funds that enable accredited investors to access a diverse portfolio of investments across various types, sectors, stages, and geographies.
Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and located in Pasadena, California. As a subsidiary of Alexandria Real Estate Equities, the firm specializes in seed, early-stage, and growth capital investments primarily within the healthcare sector. Its focus areas include biopharma, diagnostics, life sciences, research tools, agrifood technology, and technology. By leveraging its extensive industry expertise and a robust network of relationships with leading investors and scientific advisors, Alexandria Venture Investments aims to support innovative companies that are developing breakthrough technologies and therapies to enhance human health.
New Enterprise Associates, Inc. is a private equity and venture capital firm founded in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investing across various stages of business development, from seed funding to public offerings, with a strong emphasis on the technology and healthcare sectors. Its investment strategy encompasses a wide range of industries, including information technology, consumer internet, financial technology, software, healthcare services, life sciences, biopharmaceuticals, and energy technology. New Enterprise Associates actively engages with entrepreneurs to support the growth of their companies, making investments between $0.05 million and $20 million. The firm has a global investment focus, particularly in regions such as Asia, Brazil, and the United States.
Janus Henderson Investors is a global asset management firm headquartered in London, United Kingdom, with a history dating back to 1934. The company specializes in delivering investment performance and services to a diverse clientele, including institutional, retail, and high-net-worth clients. It connects these clients with investment professionals who have expertise across a wide range of asset classes, such as equities, fixed income, real estate, and alternative investments. Janus Henderson Investors aims to provide tailored investment solutions that meet the unique needs of its clients while fostering long-term financial growth.
Samsara BioCapital LLC is a principal investment firm established in 2016 and located in Palo Alto, California. The company specializes in providing investment advisory services aimed at supporting biotechnology firms and entrepreneurs in transforming their ideas into successful ventures. It focuses on sectors such as healthcare, life sciences, oncology, and digital health, emphasizing innovation in the development of new therapies. Samsara BioCapital actively seeks to partner with ambitious and visionary companies, fostering collaboration to advance significant advancements in biotechnology.
Invus Financial Advisors, LLC is an employee-owned investment firm based in New York, founded in 2006. The firm specializes in private equity investments and manages pooled investment vehicles, including hedge funds and funds of funds. Invus focuses on making direct and indirect investments in special situations, venture capital, and growth equity stages, with an emphasis on smaller companies and opportunistic co-investments. The firm adopts a flexible approach, recognizing the uniqueness of each company and the complexities of business transformation. Invus maintains a long-term commitment to its investments, aligning its incentives with those of its partners. With a history of empowering owner-managers since 1985 and a strong backing from a group of European families, Invus Financial Advisors manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong.
IndieBio, founded in 2014 and based in San Francisco, is the world’s first accelerator dedicated to startups that leverage biology to address significant global challenges. As part of SOSV, a global venture capital firm, IndieBio focuses on nurturing seed-stage and early-stage companies across various sectors, including healthcare, life sciences, biotechnology, and consumer products. The accelerator provides funding and support to innovative ventures aiming to create impactful solutions in areas such as pharmaceuticals, oncology, and advanced manufacturing. By fostering emerging technologies and biological applications, IndieBio plays a crucial role in advancing the next generation of startups that seek to make a positive difference in society.
Deerfield Management is a New York-based healthcare company founded in 1994 that operates across investment, information, and philanthropy. As a registered investment adviser, it focuses on providing a robust healthcare ecosystem through various investment strategies. The firm engages in both private and public investments, targeting companies within the life sciences, medical device, diagnostic, digital health, and health services sectors. Deerfield's commitment extends beyond financial support, as it also emphasizes the importance of information and philanthropy in enhancing healthcare outcomes.
Khosla Ventures, founded in 2004 and headquartered in Menlo Park, California, is a venture capital firm that provides strategic advice, capital, and support to bold entrepreneurs across various sectors. The firm focuses on early-stage investments in areas such as artificial intelligence, climate technology, sustainability, enterprise solutions, consumer products, fintech, digital health, medical technology, and therapeutics. Khosla Ventures is particularly interested in innovative solutions that address significant socio-economic challenges and enhance productivity, especially for low-income populations and small businesses in emerging markets. The firm embraces experimentation and is open to investing in unconventional and high-risk ventures, often acting as the sole investor in groundbreaking projects. With a commitment to fostering impactful entrepreneurship, Khosla Ventures seeks to create value through technological advancements and creative business models, with a special emphasis on markets in South Asia.
Eli Lilly and Company is a global pharmaceutical firm engaged in the discovery, development, manufacture, and sale of a wide range of medical products. The company operates facilities in the United States, Puerto Rico, and 25 other countries, distributing its products in approximately 135 countries worldwide. Eli Lilly specializes in various therapeutic areas, including neuroscience, cardiometabolic diseases, cancer, and immunology. Its key offerings include Verzenio for cancer treatment, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic conditions, as well as Taltz and Olumiant for immunological disorders. In addition to human health, the company conducts research aimed at treating diseases in animals and enhancing the efficiency of animal food production.
F-Prime Capital is a venture capital firm established in 1969 and headquartered in Cambridge, Massachusetts, with additional offices in San Francisco and London. It is part of the Fidelity Investments family, which has a long history of supporting entrepreneurs. F-Prime Capital focuses its investments on companies in North America and Europe, specializing in sectors such as healthcare, life sciences, therapeutics, fashion, medtech, health information technology and services, and technology. The firm emphasizes a hands-on approach, leveraging its deep industry expertise and extensive relationships to assist entrepreneurs in building significant companies. F-Prime Capital operates without the pressures of external fundraising, allowing it to concentrate on identifying and nurturing promising ventures.
EASME is a European Union executive agency that supports small and medium-sized enterprises and promotes innovation in Europe. It manages projects in the areas of small and medium-sized enterprises, as well as the environment, energy, and maritime sectors, funded by COSME, LIFE, and EMFF. EASME organizes the European Sustainable Energy Week and serves industries such as environmental management, energy production, and maritime activities.
General Catalyst is a venture capital firm established in 2000 and based in San Francisco, California. The firm specializes in early-stage and growth equity investments across various sectors, including consumer, enterprise, fintech, cryptocurrency, and health assurance. By fostering an environment conducive to growth, General Catalyst aims to accelerate the development of innovative ideas and companies. The firm provides mentorship and connects clients with experienced professionals to enhance their potential for success. As a Registered Investment Adviser, General Catalyst has managed a total of eight venture capital funds, accumulating approximately $3.75 billion in capital commitments.
Mission BioCapital is a venture capital firm based in Cambridge, Massachusetts, established in 2009. The firm specializes in investing in early-stage companies within the life sciences and biotechnology sectors. With a leadership team that has extensive experience in the industry, Mission BioCapital has a proven track record of launching and supporting numerous early-stage life science ventures. The firm operates in areas known for their significant research and development activities, which enhances its ability to identify promising investment opportunities. Portfolio company leaders recognize Mission BioCapital for its expertise and the substantial support it offers throughout the investment process.
Sofinnova Partners is a venture capital firm founded in 1972 and headquartered in Paris, France. The firm specializes in investing in the life sciences sector, focusing on biopharmaceuticals, biotechnology, medical devices, and industrial biotechnology. With over €2 billion in assets dedicated to life science investments, Sofinnova Partners partners with entrepreneurs at various stages, from seed to later-stage companies, including start-ups and corporate spin-offs. The firm actively seeks to take a lead role in financing, often becoming the first institutional investor in Series A rounds. It maintains an engaged presence in its portfolio companies by sitting on their boards and supporting them through to exit, thereby fostering transformative innovations that have the potential to make a significant positive impact on society.
Versant Ventures is a healthcare investment firm founded in 1999 and based in San Francisco, California. It focuses on supporting exceptional entrepreneurs in building innovative companies across various sectors within healthcare, including biotechnology, life sciences, pharmaceuticals, and oncology. With $2.3 billion under management, the firm invests at all stages of company development, emphasizing the discovery and development of novel therapeutics. Versant’s team possesses extensive investment, operational, and scientific expertise, allowing for a hands-on approach to company building. Since its inception, more than 65 companies associated with Versant have successfully achieved acquisitions or initial public offerings, reflecting the firm’s commitment to fostering growth in the healthcare industry.
RTW Investments, LP is an employee-owned hedge fund manager based in New York, with additional offices in London and Shanghai. Established in 2009, the firm specializes in investments within the healthcare sector, focusing on life sciences, big data, and digital health. RTW Investments engages in a comprehensive investment strategy that spans the entire lifecycle of healthcare companies, including company creation, early-stage venture capital, alternative financing, and public company investments. The firm conducts thorough in-house fundamental research to inform its investment decisions, managing both pooled investment vehicles and separate client-focused equity and fixed income portfolios.
Polaris Partners is a multibillion-dollar investment firm founded in 1996 and headquartered in Boston, Massachusetts, with an additional office in San Francisco. The firm specializes in investing in healthcare and biotechnology companies, focusing on various aspects of the sector. Its healthcare portfolio includes companies that develop innovative care delivery models, such as digital health solutions, consumer-centric services, patient-provider interactions, as well as data science and analytics. In the biotechnology realm, Polaris targets life sciences firms engaged in research and development of therapeutics, genomic technologies, and molecular platforms. With over 20 years of experience, Polaris Partners collaborates with repeat entrepreneurs and innovators, supporting ventures from their inception through to profitable growth.
The Bill & Melinda Gates Foundation is an independent non-profit organization based in Seattle, Washington, established in 2000. It is dedicated to reducing global inequities by focusing on improving health, alleviating extreme poverty, and supporting educational initiatives. The foundation also engages in community giving within the Pacific Northwest, promoting strategies and programs that assist low-income families. With regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom, the foundation is governed by its co-founders, Bill and Melinda Gates, along with trustee Warren Buffett. Its mission encompasses a wide range of global challenges, aiming to create lasting change through targeted grant-making and programmatic efforts.
Biotechnology Value Fund is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments. Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies while performing rigorous diligence and on-going monitoring of its investments. BVF is committed to working with its portfolio companies as partners in their successes.
Pfizer is a global biopharmaceutical company dedicated to advancing medical care and improving patient outcomes through the development and provision of safe, effective, and affordable medicines. The company offers a diverse portfolio of products that support wellness, prevention, and treatment across a wide range of therapeutic areas. Pfizer is notable for its industry-leading pipeline of innovative treatments aimed at addressing significant health challenges, including diseases such as Alzheimer's and cancer. The company's commitment to public health underpins its efforts to ensure that all individuals have access to necessary healthcare services and medications. Through its continuous focus on research and development, Pfizer seeks to enhance its offerings and contribute to the advancement of global health.
Bain Capital Life Sciences Investors, LLC is a principal investment firm based in Boston, Massachusetts, focusing on investments in the life sciences sector. The firm specializes in various types of investments, including inflection capital, growth capital, buyouts, and turnaround investments. It targets biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies worldwide. Bain Capital Life Sciences aims to support companies that drive medical innovation and address unmet medical needs, providing not only capital but also strategic assistance to enhance their growth and value during critical phases. The firm's unique expertise in the life sciences landscape allows it to effectively navigate complex investment opportunities and contribute to advancements in healthcare.
Venture Kick, a private philanthropic initiative, provides as much 150,000 Swiss francs in pre-seed funding to Swiss startups and offers structured, entrepreneurial training to build robust, winning businesses. Entrepreneurs pitch for finance as many as three times, as they compete for increasing amounts of funding at each stage. Founders gain direct feedback from the expert juries and access to an international network of successful entrepreneurs and investors. Venture Kick has supported 600 Swiss startup projects with 24.9 million francs to date. Supported projects have incorporated as 454 active companies, creating 6,033 jobs, and attracting 2.49 billion francs worth of subsequent investment. Companies founded by Venture Kick alums represented 55 percent of the TOP 100 Swiss Startup Award 2018. In 2019 Venture Kick will support idea-stage startup projects with 4.35 million francs, to bring Swiss science to global markets.
EQT Partners AB is a private equity and venture capital firm based in Stockholm, Sweden, with a global presence through additional offices in major cities across Europe, Asia, and North America. Founded in 1994, EQT specializes in a wide array of investment strategies, including expansion capital, buyouts, and growth equity, focusing on medium to large-sized companies with consistent cash flows or significant intrinsic value. The firm targets various sectors, such as healthcare, technology, energy, and infrastructure, and emphasizes investments in mid-market situations, over-leveraged companies, and distressed assets. EQT's investment approach is characterized by taking controlling or co-controlling equity stakes in its portfolio companies and actively participating in their management, often securing board seats. The firm typically holds investments for four to eight years, aiming to enhance growth and create long-term value for stakeholders.
Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz is a venture capital firm based in Menlo Park, California. The firm specializes in incubating and investing in startups across various stages, from seed to late-stage funding. It primarily focuses on sectors such as technology, including software, cloud computing, enterprise software, and consumer Internet. Additionally, it invests in emerging fields like artificial intelligence, fintech, and healthcare, specifically targeting companies at the intersection of technology and life sciences, such as digital therapeutics and computational medicine. Andreessen Horowitz is committed to fostering innovation and supporting companies that contribute to American dynamism, while strategically avoiding investments in areas like clean energy, transportation, and consumer retail.
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Gaingels is a venture investment syndicate founded in 2014 and based in Burlington, Vermont, dedicated to supporting the LGBT+ community and its allies. The organization invests in companies led by LGBT+ founders and executives at all stages of development, as well as in established firms committed to enhancing their diversity and inclusivity. With a global portfolio comprising over 130 companies and $70 million in investment capital deployed, Gaingels plays a vital role in fostering an inclusive business environment. Additionally, the Gaingels network actively assists its portfolio companies in identifying and recruiting diverse talent for their leadership teams, while cultivating a vibrant community of industry leaders, investors, and entrepreneurs committed to driving positive social change through business initiatives.
HSG, formerly known as Sequoia Capital China, is a prominent venture capital and private equity firm with a global focus on technology, healthcare, and consumer sectors. Established in 2005, HSG operates offices in key international cities including Hong Kong, Shanghai, Beijing, Shenzhen, London, Tokyo, and Singapore, managing over $55 billion in assets for leading institutional investors. The firm has supported over 1,500 companies, fostering innovation and entrepreneurship through investments in transformative technologies and high-growth business models. HSG has a track record of success, with more than 160 portfolio companies having gone public and over 140 achieving unicorn status. It has developed a comprehensive investment platform that encompasses seed, venture, growth, buyout, and infrastructure investing, as well as public equities. HSG is dedicated to empowering entrepreneurs and companies to create enduring enterprises while delivering strong returns to its limited partners. Through its extensive resources and industry expertise, HSG provides significant advantages to the companies it partners with.
Vivo Capital is a global investment firm established in 1996 and headquartered in Palo Alto, California, with additional offices in Asia. With approximately $5.8 billion in assets under management, Vivo has invested in over 290 public and private companies, primarily within the healthcare sector. The firm employs a team of 50 professionals who possess diverse expertise, including physicians, scientists, entrepreneurs, and industry executives. Vivo Capital operates as a multi-fund investment platform, engaging in strategies that encompass growth equity, private equity, venture capital, and public equity. Its investment focus spans various healthcare subsectors, including biopharmaceuticals, specialty pharmaceuticals, medical devices, and healthcare services, with an emphasis on significant healthcare markets in the United States and East Asia.
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Founded in 1986, Morningside Group is a venture capital firm based in Newton, Massachusetts. The firm seeks to invest in companies operating in the technology, internet and biotechnology sectors.
Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in promising life science companies that exhibit strong management teams and innovative technologies or business models. While its primary investment strategy targets opportunities in China, Lilly Asia Ventures is also open to exploring prospects in other regions of East and South Asia. The firm invests across various stages, including seed, early, and later stages, with particular interest in sectors such as healthcare, life sciences, oncology, manufacturing, and technology-based industries. Through its investments, Lilly Asia Ventures aims to foster the development of innovative solutions that contribute to improved health and quality of life.
Lux Capital is a venture capital firm established in 2000 and headquartered in New York, New York. The firm specializes in investments in early-stage and growth companies, focusing on sectors such as biochemistry, material science, electronics, infrastructure, and aerospace. With over $5 billion in assets under management, Lux Capital takes an active role in supporting entrepreneurs, aiming to build successful businesses in high-growth industries. The investment team has a track record of founding more than 20 companies, employing strategies that enhance connectivity, insight, and competitive leadership for its portfolio companies. As a Registered Investment Adviser, Lux Capital is committed to fostering innovation at the intersection of technology and the sciences.
Kurma Partners is a Paris-based management company founded in 2009 that focuses on financing innovation in healthcare and biotechnology. It specializes in supporting therapeutic and medical advancements from pre-creation stages to development capital. The firm is recognized as a significant player in the European market, actively investing in sectors such as life sciences, health technology, pharmaceuticals, and digital health. Kurma Partners collaborates with various prestigious research institutions and hospitals to foster innovation and growth in these fields.